- Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Neutral by Wedbush. Price target raised to $36 (71% upside) from $14.
- EnteroMedics (ETRM) downgraded to Neutral from Buy by Roth Capital Partners. Price target is $0.50 (11% upside).
- Relypsa (NASDAQ:RLYP) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target maintained at $9 (52% downside risk).
- Mirati Therapeutics (NASDAQ:MRTX) downgraded to Hold from Buy by Jefferies. Price target lowered to $17 (77% upside) from $27.
- AbbVie (NYSE:ABBV) downgraded to Market Perform from Outperform by Cowen & Company. Price target lowered to $70 (15% upside) from $77. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $65 (7% upside) from $73.
- WebMD (NASDAQ:WBMD) downgraded to Market Perform from Outperform by William Blair.
Healthcare ratings roundup - Upgrades/Downgrades
Recommended For You
About SRPT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRPT | - | - |
Sarepta Therapeutics, Inc. |